Is it Time to Dump Acurx Pharmaceuticals Inc (ACXP) Stock After it Is Down 23.78% in a Week?

Acurx Pharmaceuticals Inc (ACXP) stock is lower by 23.78% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.

Acurx Pharmaceuticals Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on ACXP!

See Full ACXP Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With ACXP Stock Today?

Acurx Pharmaceuticals Inc (ACXP) stock is down -15.83% while the S&P 500 has risen 0.4% as of 2:43 PM on Tuesday, Mar 19. ACXP is lower by -$0.41 from the previous closing price of $2.59 on volume of 252,134 shares. Over the past year the S&P 500 is up 30.83% while ACXP is lower by -28.76%. ACXP lost -$1.05 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for Acurx Pharmaceuticals Inc click here.

More About Acurx Pharmaceuticals Inc

Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. Click Here to get the full Stock Report for Acurx Pharmaceuticals Inc stock.